Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Not yet recruiting	Phase 2	2025-12-18		NCT07292207

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Aichi Cancer Center	1
Gifu University Graduate School of Medicine	2
Japanese Foundation for Cancer Research	2
Nagoya City University	5
National Cancer Center, Japan	16
Tohoku University	5
University of Tsukuba	4

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Nagoya City University	Nagoya	Japan	4